SCNLF (Scancell Holdings) EBITDA per Share: $-0.01 (TTM As of Oct. 2025)


SCNLF Scancell Holdings PLC SCNLF
20 GF Score
Price $0.28
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings EBITDA per Share?

Scancell Holdings SCNLF 20 EBITDA per Share is $-0.01 as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,141 Biotechnology companies, Scancell Holdings ranks worse than 92.64% on this metric.

Scancell Holdings's EBITDA per Share for the six months ended in Oct. 2025 was $-0.01. Its EBITDA per Share for the trailing twelve months (TTM) ended in Oct. 2025 was $-0.01.

During the past 3 years, the average EBITDA per Share Growth Rate was -37.50% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 7.40% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 4.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Scancell Holdings's EBITDA per Share or its related term are showing as below:

SCNLF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -37.5   Med: -5.3   Max: 50.9
Current: -37.5

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Scancell Holdings was 50.90% per year. The lowest was -37.50% per year. And the median was -5.30% per year.

SCNLF's 3-Year EBITDA Growth Rate is ranked worse than
92.64% of 1141 companies
in the Biotechnology industry
Industry Median: 15 vs SCNLF: -37.50

Scancell Holdings's EBITDA for the six months ended in Oct. 2025 was $-7.28 Mil.

During the past 3 years, the average EBITDA Growth Rate was -50.10% per year. During the past 5 years, the average EBITDA Growth Rate was -6.20% per year. During the past 10 years, the average EBITDA Growth Rate was -13.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Scancell Holdings was 22.00% per year. The lowest was -50.10% per year. And the median was -16.90% per year.


Scancell Holdings  (OTCPK:SCNLF) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Scancell Holdings EBITDA per Share Related Terms


Scancell Holdings EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings EBITDA per Share Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.01 -0.02 -0.01 -0.02

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.01 -0.02 0.00 -0.01
SCNLF
20GF Score
Scancell Holdings PLC SCNLF
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Scancell Holdings's EBITDA per Share for the fiscal year that ended in Apr. 2025 is calculated as

EBITDA per Share(A: Apr. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-16.698/970.318
=-0.02

Scancell Holdings's EBITDA per Share for the quarter that ended in Oct. 2025 is calculated as

EBITDA per Share(Q: Oct. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-7.282/1199.411
=-0.01

EBITDA per Share for the trailing twelve months (TTM) ended in Oct. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of $-0.01 mean?
Scancell Holdings (SCNLF) has a EBITDA per Share of $-0.01 as of Oct. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #1057 out of 1141 companies in the Biotechnology industry, placing it in the top 92.6%.
Is Scancell Holdings' EBITDA per Share too high?
Scancell Holdings' current EBITDA per Share is $-0.01. Based on the distribution chart, Scancell Holdings ranks #1057 out of 1141 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' EBITDA per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #1057 out of 1141 companies for EBITDA per Share. This places Scancell Holdings in the lower half of its industry. The industry median EBITDA per Share is 15.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Biotechnology company?
The median EBITDA per Share among Biotechnology companies is 15.00, based on 1,141 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Scancell Holdings and its competitors. For the Biotechnology industry, the median EBITDA per Share is 15.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scancell Holdings's current EBITDA per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current EBITDA per Share of $-0.01. The current EBITDA per Share is $-0.01. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current EBITDA per Share is $-0.01 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score

Get the complete analysis for SCNLF

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price